Clinical Trial Details
— Status: Not yet recruiting
Administrative data
NCT number |
NCT06440369 |
Other study ID # |
UnivFranche-Comte |
Secondary ID |
|
Status |
Not yet recruiting |
Phase |
N/A
|
First received |
|
Last updated |
|
Start date |
September 1, 2024 |
Est. completion date |
December 30, 2026 |
Study information
Verified date |
June 2024 |
Source |
University of Franche-Comté |
Contact |
n/a |
Is FDA regulated |
No |
Health authority |
|
Study type |
Interventional
|
Clinical Trial Summary
Physical activity (PA) is essential for the prevention and treatment of chronic conditions.
Despite its benefits, global physical inactivity is prevalent, contributing to chronic
diseases and premature mortality. For patients with chronic kidney disease (CKD) and
rheumatoid arthritis (RA), PA is particularly beneficial as it improves endothelial health,
reduces cardiovascular risk, diminishes inflammation, and enhances quality of life. Given the
chronic inflammation and immune system dysregulation in CKD and RA, PA may mitigate these
effects and improve patient outcomes. The primary objective of this study is to evaluate the
effects of a personalized aerobic exercise program on cardiovascular risk in patients with
CKD or RA. The secondary objectives are to assess the effects on inflammation and
immunosenescence; investigate the relationship between inflammation, immunosenescence, and
various health outcomes; compare the impacts of chronic PA and PA guidance on cardiovascular
risk, disease activity, lifestyle habits, cognitive functions, and quality of life.
This study presents an interventional design. A total of 105 subjects are expected to
participate in this study, including 45 CKD patients and 45 RA patients. Participants will be
stratified by PA level and cardiovascular risk (SCORE 2 scale) and then randomized into three
groups: Control Group: 15 CKD and 15 RA patients; Therapeutic Education Group: 15 CKD and 15
RA patients; and Experimental Group: 15 CKD and 15 RA patients.
The inclusion criteria are: age > 50 years; diagnosed with CKD or RA; glomerular filtration
rate between 45 and 29 ml/min/1.73 m² for CKD; DAS-28 score ≥ 2.6 for RA; medical clearance
for PA; informed consent and affiliation with French social security. The exclusion criteria
are: unstable corticosteroid therapy or >10 mg prednisone/day; uncontrolled hypertension;
pregnancy; cognitive impairment preventing adherence to the program; inability to perform PA;
legal incapacity or anticipated poor cooperation; lack of health insurance and participation
in an incompatible study.
The primary efficacy criterion of this study is changes in endothelial function
(macrovascular arterial stiffness) and the secondary efficacy criteria are: endothelial
function (microvascular hyperemia test); levels of inflammation and immunity (blood tests);
physical activity levels and quality of life (questionnaires); disease-related functional
impairment; disease activity and cognitive function.
Patient screening will begin with the identification of eligible patients in the Nephrology
and Rheumatology departments. Day 0 will be the selection visit for participant information
and consent. A week after Day 0, the inclusion visit and initial assessment (arterial
stiffness, endothelial function, disease impact, and blood markers for immunosenescence and
inflammation, blood pressure, heart rate, PA level, quality of life, and cognitive functions)
will be conducted for all patients. Next, only the patients in the experimental group will
carry out a 47-minute cycling intermittent exercise session, perceived exertion assessment,
and post-exercise reassessment. They will redo the assessments after the exercise. They will
have another 16 sessions of supervised exercise by a health professional and a final session
identical to the first for reassessment. Patients in the physical activity guidance group
will not undertake a physical exercise program but will receive one call per week to discuss
the physical activities performed and get answers to their questions on the subject. The
control group will continue with their usual lifestyle habits.
Description:
To address the primary objective, arterial stiffness in the experimental group will be
analyzed and compared with the control group and the physical activity orientation group. To
address the secondary objectives, various variables related to quality of life, cognitive
functions, and disease activity will be compared between different patient groups. The levels
of inflammation and immunosenescence and the relationship between these two dimensions will
be analyzed before and after the exercise program in the experimental group of RA and CKD
patients, with patients serving as their own controls.
The first contact with CKD patients will be in the Nephrology Department, and for RA
patients, in the Rheumatology Department during their regular medical visits. Initially,
investigators will screen potential patients for participation. The screening process
involves a thorough evaluation of medical characteristics, health history, and other
pre-established criteria to identify subjects who meet the specific inclusion criteria of
this study.
The evaluations described in the initial assessment will be conducted, and all enrolled
subjects will undergo a resting ECG, with the investigator recording data for each subject.
Patient treatments will not be interrupted during the entire protocol period. All patients
will be evaluated twice: once during the inclusion visit and again after 6 weeks.
During the inclusion visit, the patient will complete questionnaires, then rest in a lying
position for 10 minutes. An initial evaluation lasting about 10 minutes will be conducted in
a lying position, including measurements of blood pressure, heart rate, reactive hyperemia
(to evaluate endothelial function), and pulse wave velocity (PWV). The total duration will be
25 minutes. After then, for control group patients and physical activity orientation group
patients, the session ends here.
For experimental group patients, the patient will then perform physical activity on a cycle
ergometer for 47 minutes. The same assessments will be conducted at the end of the session
For invasive measures, venous blood samples will be taken from the elbow crease by a clinical
research nurse. A total of 2 dry tubes of 5 ml and 2 EDTA purple tubes of 5 ml will be
collected at the beginning and end of the rehabilitation protocol (6 weeks), totaling 40 ml.
For experimental groups, an additional blood sample will be taken during follow-up, 6 weeks
after the end of the rehabilitation program, totaling 60 ml for these groups.
Endothelial function will be assessed by measuring pulse wave velocity and reactive
hyperemia. Arterial compliance (central and peripheral) will be assessed by measuring the
pulse wave velocity on the carotid-femoral and carotid-radial segments, respectively, using
the Complior (Complior SP®, Artech Medical, Pantin, France). Reactive hyperemia will be
assessed with ENDOPAT (Itamar Medical®, Caesarea, Israel), which quantifies peripheral
vasodilatory response non-invasively via electronic finger cuffs following blood flow
occlusion.
Hemodynamic parameters will be evaluated by measuring heart rate and blood pressure with the
Finapres during assessments. Heart rate monitoring during cycling in experimental groups will
use the Polar A300 heart rate monitor. Blood pressure will be measured before and after
exercise with the Omron.
The interventions during the 6 weeks for the experimental group - exercise sessions will be
conducted in the nephrology or rheumatology departments, supervised by an adapted physical
activity professional, scheduled for three weekly 47-minute sessions over 6 weeks (18
sessions). Exercise intensity will be adjusted based on individual heart rate reserve,
starting at 40% and progressing to 70% by the final session. Each session includes a warm-up,
main exercise phase, and active recovery.
The interventions during the 6 weeks for the PA orientation group - Every week, for around
ten minutes, patients in the PA orientation group will be contacted by telephone. The main
objective of this exchange is to provide targeted advice on physical activity, its role, its
objectives as well as its different ways of carrying it out. The second objective is to
provide each week a personalized objective for each patient which can evolve over the weeks
in order to increase levels of physical activity as far as possible. Call Procedure are:
establishing a diagnosis carried out using questionnaires distributed beforehand (level of
physical activity, quality of life); contribution of advice and explanation around physical
activity: The evaluator (adapted physical activity teacher) will provide knowledge about PA,
its roles and objectives, recommendations, and different ways of practice; lifestyle exchange
(personalized): An exchange between the professional and the patient to understand the
patient's lifestyle habits; setting a therapeutic objective: Propose an objective around
physical activity based on the patient's needs and lifestyle and answer patient questions:
Reflective listening and open-ended questions will facilitate the exchange.